Interferon alfa-n1

DB00011

biotech approved investigational

Deskripsi

Interferon alfa-n1 consists of purified, natural (n is for natural) alpha interferon subtypes, at least two of which are glycosylated. This differs from recombinant alpha interferons, which are individual non-glycosylated proteins produced from individual alpha interferon genes.

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) 1.2 hours (mammalian reticulocytes, in vitro); >20 hours (yeast, in vivo); >10 hours (Escherichia coli, in vivo).
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Makanan

1 Data
  • 1. Avoid alcohol.

Interaksi Obat

655 Data
Denosumab The risk or severity of adverse effects can be increased when Denosumab is combined with Interferon alfa-n1.
Etanercept The risk or severity of adverse effects can be increased when Etanercept is combined with Interferon alfa-n1.
Peginterferon alfa-2a The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Interferon alfa-n1.
Interferon alfa-n3 The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Interferon alfa-n3.
Peginterferon alfa-2b The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Peginterferon alfa-2b.
Anakinra The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Anakinra.
Interferon gamma-1b The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Interferon gamma-1b.
Interferon alfa-2a The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Interferon alfa-2a.
Aldesleukin The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Aldesleukin.
Adalimumab The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Adalimumab.
Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Gemtuzumab ozogamicin.
Pegaspargase The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Pegaspargase.
Infliximab The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Infliximab.
Interferon beta-1b The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Interferon beta-1b.
Interferon alfacon-1 The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Interferon alfacon-1.
Rituximab The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Rituximab.
Basiliximab The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Basiliximab.
Muromonab The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Muromonab.
Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Ibritumomab tiuxetan.
Tositumomab The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Tositumomab.
Alemtuzumab The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Alemtuzumab.
Alefacept The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Alefacept.
Efalizumab The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Efalizumab.
Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Antithymocyte immunoglobulin (rabbit).
Interferon alfa-2b The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Interferon alfa-2b.
Daclizumab The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Daclizumab.
Phenylalanine The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Phenylalanine.
Flunisolide The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Flunisolide.
Bortezomib The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Bortezomib.
Cladribine Interferon alfa-n1 may increase the immunosuppressive activities of Cladribine.
Carmustine The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Carmustine.
Amsacrine The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Amsacrine.
Bleomycin The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Bleomycin.
Chlorambucil The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Chlorambucil.
Raltitrexed The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Raltitrexed.
Mitomycin The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Mitomycin.
Bexarotene The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Bexarotene.
Vindesine The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Vindesine.
Floxuridine The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Floxuridine.
Indomethacin The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Indomethacin.
Tioguanine The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Tioguanine.
Vinorelbine The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Vinorelbine.
Dexrazoxane The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Dexrazoxane.
Beclomethasone dipropionate The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Beclomethasone dipropionate.
Sorafenib The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Sorafenib.
Streptozocin The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Streptozocin.
Trifluridine The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Trifluridine.
Gemcitabine The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Gemcitabine.
Betamethasone The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Betamethasone.
Teniposide The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Teniposide.
Epirubicin The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Epirubicin.
Chloramphenicol The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Chloramphenicol.
Lenalidomide The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Lenalidomide.
Altretamine The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Altretamine.
Zidovudine The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Zidovudine.
Cisplatin The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Cisplatin.
Oxaliplatin The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Oxaliplatin.
Cyclophosphamide The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Cyclophosphamide.
Vincristine The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Vincristine.
Fluorouracil The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Fluorouracil.
Propylthiouracil The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Propylthiouracil.
Pentostatin The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Pentostatin.
Methotrexate The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Methotrexate.
Carbamazepine The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Carbamazepine.
Vinblastine The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Vinblastine.
Fluticasone propionate The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Fluticasone propionate.
Fluocinolone acetonide The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Fluocinolone acetonide.
Linezolid The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Linezolid.
Imatinib The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Imatinib.
Triamcinolone The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Triamcinolone.
Clofarabine The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Clofarabine.
Prednisone The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Prednisone.
Pemetrexed The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Pemetrexed.
Fludrocortisone The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Fludrocortisone.
Mycophenolate mofetil The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Mycophenolate mofetil.
Daunorubicin The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Daunorubicin.
Irinotecan The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Irinotecan.
Methimazole The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Methimazole.
Etoposide The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Etoposide.
Sulfasalazine The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Sulfasalazine.
Dacarbazine The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Dacarbazine.
Temozolomide The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Temozolomide.
Penicillamine The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Penicillamine.
Prednisolone The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Prednisolone.
Sirolimus The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Sirolimus.
Mechlorethamine The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Mechlorethamine.
Azacitidine The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Azacitidine.
Carboplatin The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Carboplatin.
Methylprednisolone The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Methylprednisolone.
Dactinomycin The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Dactinomycin.
Cytarabine The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Cytarabine.
Azathioprine The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Azathioprine.
Doxorubicin The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Doxorubicin.
Hydroxyurea The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Hydroxyurea.
Busulfan The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Busulfan.
Mycophenolic acid The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Mycophenolic acid.
Topotecan The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Topotecan.
Mercaptopurine The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Mercaptopurine.
Thalidomide The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Thalidomide.
Melphalan The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Melphalan.

Target Protein

Interferon alpha/beta receptor 1 IFNAR1
Interferon alpha/beta receptor 2 IFNAR2

Referensi & Sumber

Synthesis reference: Vladimir G. Debabov, Jury D. Tsygankov, Andrei J. Chistoserdov, Evgeny D. Sverdlov, Lara S. Izotova, Sergei V. Kostrov, Viktor E. Sterkin, Vladimir P. Kuznetsov, Sergei V. Belyaev, Galina S. Monastyrskaya, Irina S. Salomatina, Grigory M. Dolganov, Sergei G. Arsenian, Sergei A. Tsarev, Jury I. Kozlov, Alexandr Y. Strongin, Vsevolod I. Ogarkov, Jury A. Ovchinnikov, "Method for producing human leukocyte interferon alpha-2." U.S. Patent US4680260, issued January, 1982.

Contoh Produk & Brand

Produk: 2 • International brands: 1
Produk
  • Wellferon Inj 10 000 000unit/ml
    Liquid • 10000000 unit / mL • Intramuscular; Subcutaneous • Canada • Approved
  • Wellferon Inj 3000000unit/ml
    Liquid • 3000000 unit / mL • Intramuscular; Subcutaneous • Canada • Approved
International Brands
  • Wellferon — GlaxoSmithKline

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul